Education
About Us
Working with TipRanks
Follow Us
Nanjing Sinolife United Co., Ltd. Class H (HK:3332)
:3332
3332 Stock Chart & Stats
HK$0.38
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.38
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.33 - HK$0.70
Previous CloseN/A
Volume70.00K
Average Volume (3M)6.00K
Market Cap
HK$648.05M
Enterprise ValueHK$255.45M
Total Cash (Recent Filing)HK$140.84M
Total Debt (Recent Filing)HK$55.37M
Price to Earnings (P/E)21.4
Beta-0.30
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding946,298,340
10 Day Avg. Volume16,600
30 Day Avg. Volume6,000
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)1.22
Price to Sales (P/S)0.64
P/FCF Ratio-72.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained 32.5% top-line expansion signals durable demand and successful commercial execution across product lines. Over 2-6 months this underpins scale advantages, supports ongoing R&D and distribution investment, and increases resilience to market fluctuations.
Improving Gross MarginsA meaningful gross margin improvement reflects stronger pricing power or manufacturing efficiency, improving long-run cash generation per sale. Higher product-level profitability helps absorb SG&A and supports sustainable operating leverage as sales scale.
Conservative Capital StructureVery low leverage and a high equity ratio provide durable financial flexibility, lowering refinancing and default risk. This balance-sheet strength supports funding R&D, capex, or M&A without forcing distress financing over the medium term.
Bears Say
Operating Cash-Flow VisibilityAbsence of reported operating cash flow for the latest year raises material liquidity and cash-conversion concerns. Over months this undermines confidence in self-funded growth, may force external financing, and increases execution risk for capex and R&D programs.
Pressure On Operating MarginsDeclining EBIT/EBITDA margins suggest rising operating costs or less efficient scale-up, which can erode the benefits of gross-margin gains. If persistent, this reduces free cash flow conversion and limits ability to reinvest or improve returns to shareholders.
Modest Return On EquityAn ROE below double digits indicates limited efficiency in converting equity into profits. Over the medium term this may reflect suboptimal capital allocation or margin constraints, potentially limiting shareholder return compared with peers even with low leverage.
Nanjing Sinolife United Co., Ltd. Class H News
3332 FAQ
What was Nanjing Sinolife United Co., Ltd. Class H’s price range in the past 12 months?
Nanjing Sinolife United Co., Ltd. Class H lowest stock price was HK$0.33 and its highest was HK$0.70 in the past 12 months.
What is Nanjing Sinolife United Co., Ltd. Class H’s market cap?
Nanjing Sinolife United Co., Ltd. Class H’s market cap is HK$648.05M.
When is Nanjing Sinolife United Co., Ltd. Class H’s upcoming earnings report date?
Nanjing Sinolife United Co., Ltd. Class H’s upcoming earnings report date is Apr 01, 2026 which is in 55 days.
How were Nanjing Sinolife United Co., Ltd. Class H’s earnings last quarter?
Nanjing Sinolife United Co., Ltd. Class H released its earnings results on Aug 22, 2025. The company reported HK$0.017 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.017.
Is Nanjing Sinolife United Co., Ltd. Class H overvalued?
According to Wall Street analysts Nanjing Sinolife United Co., Ltd. Class H’s price is currently Overvalued.
Does Nanjing Sinolife United Co., Ltd. Class H pay dividends?
Nanjing Sinolife United Co., Ltd. Class H pays a Annually dividend of HK$0.076 which represents an annual dividend yield of N/A. See more information on Nanjing Sinolife United Co., Ltd. Class H dividends here
What is Nanjing Sinolife United Co., Ltd. Class H’s EPS estimate?
Nanjing Sinolife United Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanjing Sinolife United Co., Ltd. Class H have?
Nanjing Sinolife United Co., Ltd. Class H has 946,298,340 shares outstanding.
What happened to Nanjing Sinolife United Co., Ltd. Class H’s price movement after its last earnings report?
Nanjing Sinolife United Co., Ltd. Class H reported an EPS of HK$0.017 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nanjing Sinolife United Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3332
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanjing Sinolife United Co., Ltd. Class H
Nanjing Sinolife United Company Limited, an investment holding company, engages in the manufacture, processing, and sale of nutritional supplements in the People's Republic of China, Australia, New Zealand, Vietnam, and internationally. The company is also manufactures and sale of cosmetics and skin care products; and trading, retail, and testing of packaged health food products. It sells its products under the Good Health, Zhongsheng, Hejian, and Cobayer series through a network of retail stores. The company also sells its products through distributors, TV shopping, and e-commerce platforms; and chain pharmacies, health goods supermarkets, and tourist souvenir shops. Nanjing Sinolife United Company Limited was incorporated in 1999 and is headquartered in Nanjing, China.
Technical Analysis
Ming Fai International Holdings
―
Natural Beauty Bio-Technology
―
China Ludao Technology Co. Ltd.
―
EC Healthcare
―
UNQ Holdings Limited
―